Business Segments Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.37 CNY | +1.06% |
|
-3.81% | +1.18% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Gross Profit: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Clinical-Related and Laboratory Services | - | - | 2.88B | 3.12B | 3.3B | |||||
Gross Profit | - | - | 1.2B | 1.19B | 1.21B | |||||
Clinical Trial Solutions | - | - | 4.13B | 4.17B | 3.18B | |||||
Gross Profit | - | - | 1.55B | 1.59B | 940M | |||||
Service Industry | 3.19B | 5.21B | - | - | - | |||||
Total Assets | 19.51B | 23.74B | - | - | - | |||||
Interest Expense | -50.78M | -24.91M | - | - | - | |||||
Income Tax Expense | 190M | 293M | - | - | - | |||||
CAPEX | -156M | -369M | - | - | - | |||||
EBT | 2.22B | 3.68B | - | - | - | |||||
D&A | 145M | 189M | - | - | - | |||||
Operating Income | 2.22B | 3.7B | - | - | - | |||||
Net Income | 1.75B | 2.87B | - | - | - | |||||
Unallocated Other | - | - | 83.93M | 94.93M | 129M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
China | 1.91B | 2.76B | 3.6B | 4.23B | 3.55B | |||||
Overseas | 1.29B | 2.46B | 3.48B | 3.15B | 3.06B |
Select your edition
All financial news and data tailored to specific country editions
